VeriStrat ® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

British Journal of Cancer

Volumn 107, Issue 11, 2012, Pages 1820-1825

  Kuiper, J L ^a   Lind, J S W ^a   Groen, H J M ^b   Roder, J ^c   Grigorieva, J ^c   Roder, H ^c   Dingemans, A M C ^d   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c BIODESIX INC   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

erlotinib; lung cancer; personalised therapy; proteomics; serum biomarker; sorafenib

Indexed keywords

ERLOTINIB; SORAFENIB;

ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84870065029     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.470     Document Type: Article

References (27)

1. Akerley WL, Rich NT, Egbert L, Harker WG, Van Duren T, Smit J, Hoffman JM (2010) Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC). J Clin Oncol 28(15 Suppl): e18008
2. Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP (2010) Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 5: 169-178
3. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R (1986) Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39: 794-797
4. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397-405
5. Carbone DP, Ding K, Roder H, Tsao M, Shepherd FA, Seymour L (2010a) Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib or placebo in the NCIC CTG BR.21 trial. J Thorac Oncol 5(Suppl 1): abstract number 2030. 2010a
6. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP (2010b) VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 69: 337-340
7. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE (2010) Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 19: 358-365
8. Dingemans AM, de Langen AJ, van dB V, Marcus JT, Backes WH, Scholtens HT, van TH, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF, Groen HJ (2011) First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 22: 559-566
9. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 131: 911-92
10. Gautschi O, Dingemans AC, Crowe S, Roder H, Zappa F, Pless M, Brustche M, Peters S, Carbone D, Smit EF (2012) Serum proteomic classifier for patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab in the first line: pooled analysis of phase II trials SAKK 19/05 and NTR528. Presented at III European Lung Cancer Conference. (Geneva, Switzerland
11. Gregorc V (2009) Prospective studies with proteomics. Presented at 13th World Conference on Lung Cancer. ; 4 August 2009; San Francisco
12. Grigorieva J, Quoix E, Wislez M, Moro-Sibilot D, Merle P, Gervais R, Friard S, Rouveau R, Roder H, Roder J, Morin F, Cadranel J (2011) Evaluation of VeriStrat signature in advanced bronchioloalveolar carcinoma (BAC): a Pooled analysis of IFCT-0401 and 0504 trials. Poster Presentation at 14th World Conference on Lung Cancer. ; 3-7 July 2011; Amsterdam, pp 2.214
13. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-1854
14. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243-3256
15. Hunsucker SW, Grigorieva J, Helfrich BA, Allen J, Bunn PA, Roder H (2011) Pretreatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affects sensitivity of lung cancer cell lines to EGFR-TKIs. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research. ; 2-6 April 2011; Orlando, Florida. AACR: Philadelphia (PA), abstract number LB-306
16. Kokubun M, Imafuku Y, Okada M, Ohguchi Y, Ashikawa T, Yamada T, Yoshida H (2005) Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. Clin Chim Acta 360: 97-102
17. Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Vigano MG, Sorlini C, Ghio D, Tsypin M, Bulotta A, Bergamaschi L, Gregorc V (2012) Changes in Plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol 7: 40-48
18. Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA, Honeywell RJ, Giovannetti E, Peters GJ, Postmus PE, van Suylen RJ, Smit EF (2010) A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 16: 3078-3087
19. Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, Gregorc V, Bachi A (2012) SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics; e-pub ahead of print 4 July 2012; doi: 10.1016/j.jprot.2012.06.022
20. Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer. J Clin Oncol 25: 587-595
21. Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van KM, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132
22. Sorlini C, Barni S, Petrelli F, Novello S, De Marinis F, De Pas TM, Grossi F, Bearz A, Mencoboni M, Aieta M, Caprioli A, Antonelli P, Zilembo N, Bachi A, Floriani I, Roder H, Roder J, Grigorieva J, Lazzari C, Gregorc V (2011) PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). J Clin Oncol 29(Suppl): abstract TPS214
23. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn Jr. PA, Carbone DP (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99: 838-846
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
25. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285
26. Venet D, Dumont JE, Detours V (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7: e1002240
27. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362: 433-439